4DMedical (formerly 4Dx) is a medical technology company based in Melbourne, Australia founded by ALHI Principal Investigator, Prof Andreas Fouras, PhD. 4DMedical’s FDA cleared and TGA approved XV Lung Ventilation Analysis Software platform is a world-first, providing a state-of-the-art, non-invasive way of understanding regional lung motion and airflow in real-time within the breathing lungs. This enables highly detailed maps of patterns of lung motion and pulmonary function, with functional deficits detected through local differences in movement. The end result: improving millions of lives through earlier disease detection and more accurate monitoring of chronic respiratory conditions.
Having raised millions of dollars in research funding from agencies including Australia’s National Health & Medical Research Council and the American Asthma Foundation, the team has positioned itself as an unrivaled leader in the race to deliver world changing medical technology breakthroughs.
For more information about 4DMedical, go to: 4DMedical.com